ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Abstracts tagged "Spondylarthritis and tumor necrosis factor (TNF)"

  • Abstract Number: 276 • ACR/ARHP Annual Meeting 2018

    Gender Differences in TNFi Treatment Adherence and Response in As Patients: A Prospective Longitudinal Cohort Study

    S. Hoekstra1, Tamara Rusman2, Michael T. Nurmohamed3, Christiaan van Denderen4 and Irene van der Horst-Bruinsma5, 1Rheumatology, VU Univeresity Medical Center, Amsterdam, Netherlands, 2Rheumatology, VU University medical centre, Amsterdam, Netherlands, 3Rheumatology, Amsterdam Rheumatology and immunology Center, VU University Medical Center, Amsterdam, Netherlands, 4Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, 5Rheumatology, VU University Medical Center, Amsterdam, Netherlands

    Background/Purpose: Despite several observations of gender differences in TNF inhibitor (TNFi) treatment response and adherence in ankylosing spondylitis (AS) patients, limited studies were conducted. Our…
  • Abstract Number: 2598 • ACR/ARHP Annual Meeting 2018

    Efficacy of Anti-Tumor Necrosis Factor (TNF) Alpha Therapy, in Patients with Spondylarthritis in the University Center of Rouen in France, Divived to the Berlin Algorithm Modified By the Assessement Spondylarthritis Group: A Ten Years Retrospective Study

    Christelle Princivil1, thierry Lequerre2, Didier Alcaix3 and Olivier Vittecoq4, 1Jacques Monod hospital center, 76290 Montivilliers, France, montivilliers, France, 2Rheumatology Department, Rouen University Hospital, University of Rouen, 76031 Rouen, France., ROUEN, France, 3Rheumatology Department, Jacques Monod Hospital Center, 76290 Montivilliers, France, montivilliers, France, 4INSERM U905 & Normandy University, Institute for Research and Innovation in Biomedicine, Rouen, France

    Background/Purpose: Treatments and diagnosis of SpA is a public health problem. The efficacy of anti-TNF alpha treatment is different from one patient to an other.…
  • Abstract Number: 1547 • ACR/ARHP Annual Meeting 2017

    Dose Tapering of TNFi in Patients with Axial Spondyloarthritis: An Observational Cohort Study from Nationwide Korean College of Rheumatology Biologic Registry (KOBIO)

    Jun Won Park1, Jin Kyun Park1, Kichul Shin2, Yong-Beom Park3, Eun Bong Lee1, Yeong Wook Song4 and Eun Young Lee1, 1Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), 2Kyungnam villa #102, Division of Rheumatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of (South), 3Yonsei University Severance Hospital, Seoul, Korea, Republic of (South), 4Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South)

    Background/Purpose: To compare the clinical efficacy of dose-tapering strategy of tumor-necrosis factor inhibitor (TNFi) with that of standard-dose TNFi treatment in patients with spondyloarthritis (SpA)…
  • Abstract Number: 2463 • ACR/ARHP Annual Meeting 2017

    Golimumab in Biologic-NaïVe Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) or Ankylosing Spondylitis (AS) – Subanalysis from a Non-Interventional Evaluation in Germany

    Klaus Krüger1, Gerd R. Burmester2, Siegfried Wassenberg3, Martin Bohl-Buehler4 and Matthias H. Thomas5, 1Praxiszentrum St. Bonifatius München, München, Germany, 2Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany, 3Rheumazentrum Ratingen, Ratingen, Germany, 4Friedrich-Ebert-Str. 35, Rheumahaus, Potsdam, Germany, 5Medical Affairs, MSD Sharp & Dohme GmbH, Bünde, Germany

    Background/Purpose: Golimumab (GLM) has demonstrated efficacy and safety in several randomized clinical trials with biologic-naïve patients (pts.). However, more data regarding the effectiveness and patient-reported…
  • Abstract Number: 2481 • ACR/ARHP Annual Meeting 2017

    Long-Term Safety of Adalimumab (HUMIRA) in Adult Patients from Global Clinical Trials across Multiple Indications: An Updated Analysis in 29,987 Patients Representing 56,951 Patient-Years

    Gerd R. Burmester1, Remo Panaccione2, Kenneth B. Gordon3, James T. Rosenbaum4, Dilek Arikan5, Winnie L. Lau5 and Rita Tarzynski-Potempa5, 1Charité - University Medicine Berlin, Berlin, Germany, 2University of Calgary, Calgary, AB, Canada, 3Medical College of Wisconsin, Milwaukee, WI, 4Ophthalmology, Oregon Health & Science University and Legacy Devers Eye Institute, Portland, OR, 5AbbVie Inc., North Chicago, IL

    Background/Purpose: Adalimumab is an anti–tumor necrosis factor-α (TNF-α) agent indicated for the treatment of immune-mediated diseases. The long-term safety of adalimumab was previously reported in…
  • Abstract Number: 2725 • ACR/ARHP Annual Meeting 2016

    Elevated Disease Activity in Disease-Related Spondyloarthritis Despite Use of Tumor Necrosis Factor Inhibitor Therapies

    Delamo Bekele1, Ryan Duong2, Patrick R. Wood3, Mena Hashim4, Jason Hou5, Jessica Walsh6, Maureen Dubreuil7,8, Daniel Clegg9, Prashant Kaushik10, Bernard Ng11,12, Elizabeth Chang13, Andreas M. Reimold14, Liron Caplan15 and Gail S. Kerr16, 1Medicine, Howard University Hospital, Washington, DC, 2Rheumatology, Denver Veterans Affairs Medical Center and UC Denver SOM, Denver, CO, 3Internal Medicine, University of Colorado School of Medicine, Aurora, CO, 4Denver VAMC, Denver, CO, 5Gastroenterology, Houston VAMC and Baylor College of Medicine, Houston, TX, 6Division of Rheumatology, Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT, 7Rheumatology, Boston VA HealthCare System, Boston, MA, 8Rheumatology, Boston University Medical Center, Boston, MA, 9Rheumatology, Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT, 10Rheumatology/Medicine, Stratton VAMC, Albany, NY, 11Division of Rheumatology, Department of Medicine, University of Washington, Seattle, WA, 12Rheumatology, VA Puget Sound Healthcare System, Seattle, WA, 13Rheumatology, Veterans Affairs, Phoenix, AZ, 14Rheumatology, VAMC and University of Texas Southwestern, Dallas, TX, 15Div of Rheumatology, Denver VA and University of Colorado School of Medicine, Aurora, CO, 16Washington DC VAMC, Georgetown University Hospital, Howard University Hospital, Washington, DC

    Background/Purpose:   Spondyloarthritis (SpA) includes a wide range of overlapping diseases for which there are a limited number of approved pharmacologic agents that have been…
  • Abstract Number: 1916 • ACR/ARHP Annual Meeting 2014

    Stromal Overexpression of Transmembrane TNF Induces Spa-like Arthritis and Spondylitis in Mice

    Leonie M. van Duivenvoorde1,2, Melissa N. van Tok3 and Dominique L. Baeten1,4, 1Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, 2Experimental Immunology, Department of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands, 3Department of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands, 4Experimental Immunology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands

    Background/Purpose: The immunopathology of spondyloarthritis (SpA) is determined by inflammation and structural damage, in particular osteoproliferation, of axial and peripheral joints. The failure of TNF…
  • Abstract Number: 2467 • ACR/ARHP Annual Meeting 2013

    Response to Tumor Necrosis Factor inhibitors In Axial Spondyloarthritis: Does Sacroiliitis Make Any Difference?

    Julien Girodon1, Vianney Jouhet2 and Elisabeth Solau-Gervais1, 1Rheumatology, University Hospital of Poitiers, Poitiers, France, 2Informatic, University hospital Bordeaux, Bordeaux, France

    Background/Purpose: Axial spondyloarthritis (SpA) are characterized by sacroiliitis. The TNF inhibitors (TNFi) have been proven to be highly effective in ankylosing spondylitis. Recently, adalimumab demonstrate…
  • Abstract Number: 536 • ACR/ARHP Annual Meeting 2013

    Membrane-Bound TNF Drives Axial and Peripheral Inflammation and Pathologic New Bone Formation

    Leonie M. van Duivenvoorde1, Melissa N. van Tok1 and Dominique L. Baeten2, 1Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, 2Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands

    Background/Purpose: The morbidity of spondyloarthritis (SpA) is determined not only by inflammation but also by structural damage, in particular osteoproliferation leading to joint ankylosis. The…

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology